Cargando…
Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic, systemic, and autoimmune disease, whose etiology is still unknown. Although there has been progress in the treatment of SLE through the use of glucocorticoid and immunosuppressive drugs, these drugs have limited efficacy and pose significant risks of...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373075/ https://www.ncbi.nlm.nih.gov/pubmed/22701487 http://dx.doi.org/10.1155/2012/718237 |
_version_ | 1782235404558139392 |
---|---|
author | Yoshimi, Ryusuke Ishigatsubo, Yoshiaki Ozato, Keiko |
author_facet | Yoshimi, Ryusuke Ishigatsubo, Yoshiaki Ozato, Keiko |
author_sort | Yoshimi, Ryusuke |
collection | PubMed |
description | Systemic lupus erythematosus (SLE) is a chronic, systemic, and autoimmune disease, whose etiology is still unknown. Although there has been progress in the treatment of SLE through the use of glucocorticoid and immunosuppressive drugs, these drugs have limited efficacy and pose significant risks of toxicity. Moreover, prognosis of patients with SLE has remained difficult to assess. TRIM21/Ro52/SS-A1, a 52-kDa protein, is an autoantigen recognized by antibodies in sera of patients with SLE and Sjögren's syndrome (SS), another systemic autoimmune disease, and anti-TRIM21 antibodies have been used as a diagnostic marker for decades. TRIM21 belongs to the tripartite motif-containing (TRIM) super family, which has been found to play important roles in innate and acquired immunity. Recently, TRIM21 has been shown to be involved in both physiological immune responses and pathological autoimmune processes. For example, TRIM21 ubiquitylates proteins of the interferon-regulatory factor (IRF) family and regulates type I interferon and proinflammatory cytokines. In this paper, we summarize molecular features of TRIM21 revealed so far and discuss its potential as an attractive therapeutic target for SLE. |
format | Online Article Text |
id | pubmed-3373075 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-33730752012-06-14 Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus Yoshimi, Ryusuke Ishigatsubo, Yoshiaki Ozato, Keiko Int J Rheumatol Review Article Systemic lupus erythematosus (SLE) is a chronic, systemic, and autoimmune disease, whose etiology is still unknown. Although there has been progress in the treatment of SLE through the use of glucocorticoid and immunosuppressive drugs, these drugs have limited efficacy and pose significant risks of toxicity. Moreover, prognosis of patients with SLE has remained difficult to assess. TRIM21/Ro52/SS-A1, a 52-kDa protein, is an autoantigen recognized by antibodies in sera of patients with SLE and Sjögren's syndrome (SS), another systemic autoimmune disease, and anti-TRIM21 antibodies have been used as a diagnostic marker for decades. TRIM21 belongs to the tripartite motif-containing (TRIM) super family, which has been found to play important roles in innate and acquired immunity. Recently, TRIM21 has been shown to be involved in both physiological immune responses and pathological autoimmune processes. For example, TRIM21 ubiquitylates proteins of the interferon-regulatory factor (IRF) family and regulates type I interferon and proinflammatory cytokines. In this paper, we summarize molecular features of TRIM21 revealed so far and discuss its potential as an attractive therapeutic target for SLE. Hindawi Publishing Corporation 2012 2012-06-04 /pmc/articles/PMC3373075/ /pubmed/22701487 http://dx.doi.org/10.1155/2012/718237 Text en Copyright © 2012 Ryusuke Yoshimi et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Yoshimi, Ryusuke Ishigatsubo, Yoshiaki Ozato, Keiko Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus |
title | Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus |
title_full | Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus |
title_fullStr | Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus |
title_full_unstemmed | Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus |
title_short | Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus |
title_sort | autoantigen trim21/ro52 as a possible target for treatment of systemic lupus erythematosus |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373075/ https://www.ncbi.nlm.nih.gov/pubmed/22701487 http://dx.doi.org/10.1155/2012/718237 |
work_keys_str_mv | AT yoshimiryusuke autoantigentrim21ro52asapossibletargetfortreatmentofsystemiclupuserythematosus AT ishigatsuboyoshiaki autoantigentrim21ro52asapossibletargetfortreatmentofsystemiclupuserythematosus AT ozatokeiko autoantigentrim21ro52asapossibletargetfortreatmentofsystemiclupuserythematosus |